在慢性自发性疹中使用雷米布鲁丁尼布:来自两个第三阶段研究的52周结果
Ana Maria Giménez-Arnau1, Robert Szalewski2, Michihiro Hide3
1Department of Dermatology, Hospital del Mar and Research Institute, Universitat Pompeu Fabra, Barcelona, Spain.
The Journal of allergy and clinical immunology
|October 20, 2025
概括
雷米布鲁丁尼布 (布鲁顿氨酸激酶抑制剂) 为慢性自发性疹症 (CSU) 症状提供了持续的长期缓解. 在CSU患者中,口服药物在52周内表现出良好的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性自发性疹 (CSU) 是一种使人衰弱的疾病,通常不耐标准治疗.
- 第二代H1抗胰岛素是第一线治疗,但许多患者仍然有症状.
- 布鲁顿氨酸激酶 (BTK) 抑制剂代表了CSU的新型治疗方法.
研究的目的:
- 评估雷米布鲁丁尼布在CSU患者的长期疗效和安全性.
- 为了评估持续的疾病控制和Remibrutinib在52周的耐受性.
主要方法:
- 进行了两个随机的,安慰剂控制的3期研究 (REMIX-1和REMIX-2).
- 患者接受了口服雷米布鲁丁尼布25毫克每天两次或安慰剂24周,随后是开放期长达52周.
- 主要终点是第12周每周疹活动评分 (UAS) 与基线的变化.
主要成果:
- 与基线相比,雷米布鲁丁尼在52周的UAS得分持续显著改善.
- 从安慰剂转换为雷米布鲁丁尼布的患者经历了快速和持续的症状改善.
- 不良事件发生率,严重不良事件和停药率与长达52周的短期数据保持一致.
结论:
- 雷米布鲁丁尼布为CSU患者提供持续的疗效,CSU患者的抗组胺药物控制不足.
- 该药物表现出一致且有利的长期安全性.
- 雷米布鲁丁尼布是治疗慢性自发性疹症的一个有前途的治疗选择.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...